Methods of treating inflammatory and autoimmune diseases with natalizumab

ABSTRACT

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn&#39;s Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

PRIORITY CLAIM

This application is a continuation of U.S. application Ser. No.15/285,381, filed Oct. 4, 2016, which is a continuation of U.S.application Ser. No. 12/757,305, filed Apr. 9, 2010, now U.S. Pat. No.9,493,567, which is a divisional of U.S. application Ser. No.11/711,628, filed Feb. 28, 2007 (now abandoned), which claims thebenefit of priority under 35 USC Section 119(e) to U.S. ProvisionalPatent Application No. 60/776,931, filed Feb. 28, 2006, the entirecontents of each of which are hereby incorporated herein for allpurposes.

TECHNICAL FIELD

The invention relates to methods of treating inflammatory and autoimmunediseases with a recombinant antibody. These methods improve the safetyof treatment by informing and monitoring patients undergoing antibodytreatment.

BACKGROUND ART

The migration of lymphocytes from the peripheral blood across the bloodbrain bather has been reported to initiate the development of severalcentral nervous system (CNS) inflammatory diseases. Lymphocyte entryinto the CNS is mediated by cellular adhesion molecules (O'Neill et al.,Immunology 72:520-525 (1991); Raine et al., Lab. Invest. 63:476-489(1990); Yednock et al., Nature 356:63-66 (1992); Baron et al., J. Exp.Med. 177:57-68 (1993); Steffen et al., Am. J. Path. 145:189-201 (1994);Christensen et al., J. Immunol. 154:5293-5301 (1995)).

Cellular adhesion molecules present on the cell surface mediate thedirect binding of one cell to another (Long et al., Exp. Hematol.20:288-301 (1992)). The integrin and immunoglobulin supergene familiesof adhesion molecules regulate lymphocyte traffic into the CNS (Hemleret al., Annu. Rev. Immunol. 8:365-400 (1990); Springer et al., Cell76:301-314 (1994); Issekutz et al., Curr. Opin. Immunol. 4:287-293(1992)). Adhesion molecules have been widely reported to mediateinflammatory and autoimmune diseases, for example, asthma, Alzheimer'sdisease, atherosclerosis, AIDS dementia, diabetes, inflammatory boweldisease, multiple sclerosis, rheumatoid arthritis, tissuetransplantation rejection, and tumor metastasis.

Integrins are heterodimers of non-covalently linked α and β chains(Hemler et al., Annu. Rev. Immunol. 8:365-400 (1990)). The α4β1 (alsocalled very late activation antigen-4 VLA-4) and α4β7 integrins arepresent on the surface of most types of white blood cells, where theymediate white cell binding to endothelial cells by interacting withtheir cognate receptors, vascular cell adhesion molecule-1 (VCAM-1) andmucosal addressin cellular adhesion molecule-1 (MAdCAM-1), on theendothelial cell surface. Integrins are believed to play an importantrole in immune cell adhesion to the endothelial cell layer on bloodvessels, facilitating their subsequent migration into inflamed tissues.Several studies implicate VLA-4 and, in particular the α4 integrinsubunit, in CNS inflammation (Yednock et al., Nature 356:63-66 (1992);Baron et al., J. Exp. Med. 177:57-68 (1993); Steffen et al., Am. J.Path. 145:189-201 (1994); Christensen et al., J. Immunol. 154:5293-5301(1995). It has also been reported that VCAM-1 expression is elevated ininflamed brain tissue relative to normal brain tissue (Cannella andRaine, Ann. Neurol. 37:424-435 (1995); Washington et al., Ann. Neurol.35:89-97 (1994); Dore-Duffy et al., Frontiers in Cerebral VascularBiology: Transport and Its Regulation, 243-248 (Eds. Drewes & Betz,Plenum, N.Y. 1993)).

The interaction between α4β1 and its targets is a component of theinflammation that takes place in the CNS of patients with multiplesclerosis (MS). Under normal conditions, VCAM-1 is not expressed in thebrain parenchyma. However, in the presence of pro-inflammatorycytokines, VCAM-1 is upregulated on endothelial cells and on microglialcells near the sites of inflammation (Elices et al., Cell 60:577-584(1990); Lobb and Hemler, J. Clin. Invest. 94:1722-1728 (1994); Petersonet al., J. Neuropathy Exp. Neurol. 61:539-546 (2002)). Further,osteopontin, which exhibits many properties of a proinflammatorycytokine, is also upregulated in MS lesions (Chabas et al., Science294:1731-1735 (2001)).

MS is a serious and disabling inflammatory and autoimmune disease ofyoung adults, with a peak age of onset in the third decade of life. Mostindividuals present with the relapsing-remitting form of the disease andexperience recurrent attacks, which, over time, result in accumulatingpermanent physical disability and cognitive decline. About 70% of theseindividuals will eventually enter a phase of progressive neurologicaldecline (secondary progressive MS), with or without superimposedrelapses. Current treatments are minimally effective for secondaryprogressive MS. The majority of patients suffer permanent neurologicaldysfunction and, on average, have a life expectancy of six to sevenyears after the onset of disease.

Currently, four therapies are approved in the United States for thetreatment of relapsing forms of MS. The interferons, BETASERON®(interferon (β-lb SC (subcutaneous)), AVONEX® (interferon β-la IM(intramuscular)), and REFIF® (interferon β-la SC), are cytokines withantiviral, antiproliferative, and immunomodulatory activities. COPAXONE®(glatiramer acetate) is a mixture of synthetic polypeptides with apoorly understood mechanism of action. The β-interferons can produceserious adverse events and some evidence suggests that COPAXONE® isineffective (Munari, et al., The Cochrane Library, Issue 1, Chichester,UK:—John Wiley & Sons, Ltd. (2004)).

Serious adverse events of β-interferons include rare reports ofhypersensitivity reactions, depression and suicide, decreased peripheralblood counts, hepatic injury, cardiomyopathy, and various autoimmunedisorders (BETASERON® Package Insert, 2003; REFIF® Package Insert, 2004;AVONEX® Package Insert, 2005). The development of neutralizingantibodies to interferons is associated with a loss of efficacy.Antibodies that develop to a β-interferon cross-react with otherinterferons leading to loss of efficacy for the entire class in suchpatients (IFNB MS Study Group, Neurology 47:889-894 (1996); PRISMS StudyGroup, Neurology 56:1628-1636 (2001); Kappos et al., Neurology 65:40-47(2005)). As a result, in the United States alone, over 50,000 patientswho were previously treated no longer receive therapy. Thus, there is alarge group of patients with active MS who are currently not receivingany approved therapy.

Among those patients who do receive treatment, a significant numbercontinue to experience disease activity, as observed clinically and bymagnetic resonance imaging (MRI). Although a variety of therapeuticstrategies are currently used in clinical practice to managebreakthrough disease while on treatment (e.g., switching therapy,changing dose and frequency of interferon, combination therapy), thesimilar efficacy between available medications and lack of clinical datademonstrating the effectiveness of any of these strategies inbreakthrough patients makes the decision of what to do for thesepatients largely empirical. Each of the partially effective approvedmedications leads to an approximately 30% reduction in relapse rate andlimited impact on disability progression (IFNB MS Study Group, Neurology43:655-661 (1993); Jacobs et al., Ann. Neurol. 39:285-289 (1996); PRISMSStudy Group, Lancet 352:1498-1504 (1998)); Johnson et al., Neurology45:1268-1276 (1995)). Data from the Phase 3 trials of β-interferon in MSshow that 62% to 75% of subjects experienced at least one relapse duringthese 2-year trials despite interferon treatment (IFNB MS Study Group,Neurology 43:655-661 (1993); Jacobs et al., Ann. Neurol. 39:285-289(1996); PRISMS Study Group, Lancet 352:1498-1504 (1998)). Similarly, 66%of subjects in the Phase 3 MS trial of glatiramer acetate experienced atleast one relapse during the 2-year period, a proportion that was notsignificantly different from placebo (Johnson et al., Neurology45:1268-1276 (1995)).

Progressive Multifocal Leukoencephalopathy (PML) is a severe, rapidlyprogressive disease that destroys the myelin coating which protectsnerve cells. PML occurs almost exclusively in severely immunosuppressedpatients and is frequently associated with lymphoproliferative and otherchronic diseases, such as AIDS, Hodgkin's disease, chronic lymphocyticleukemia, sarcoidosis, tuberculosis, systemic lupis erythematosis, andorgan transplantation. JC virus (JCV) is the etiological agent of PMLand may result from a primary infection or follow reactivation of latentvirus.

Natalizumab, an α4-integrin antagonist, has been used successfully totreat diseases with inflammatory and/or autoimmune components, forexample, MS, Crohn's Disease, and rheumatoid arthritis. There are threeknown cases of PML occurring during or after administration ofnatalizumab, two proved fatal and one patient recovered. All three casesoccurred in patients on concomitant medications which may havecontributed to immunosuppression.

Thus, there is a need in the art for determining the relationshipbetween natalizumab treatment and the occurrence of PML and for safermethods of treating patients with natalizumab that take into account thepossibility of contracting PML.

SUMMARY

The invention provides safer methods of using natalizumab to treatpatients with inflammatory and autoimmune diseases.

In a first aspect, the invention provides a method of using natalizumabto treat a patient with an inflammatory or autoimmune disease byadministering a pharmaceutically effective amount of natalizumab;monitoring the patient for indicators of progressive, multifocalleukoencephalopathy; and discontinuing the administration of natalizumabin the presence of indicators of progressive multifocalleukoencephalopathy; wherein the monitoring improves the safety of thetreatment. In embodiments of the method the disease is multiplesclerosis. In embodiments the multiple sclerosis is selected fromrelapsing remitting, secondary progressive, primary progressive, andchronic progressive multiple sclerosis. In embodiments of the method thedisease is inflammatory bowel disease or rheumatoid arthritis. Inembodiments the inflammatory bowel disease is Crohn's Disease. Inembodiments of the method the monitoring detects JCV in the patient'surine, blood, and/or cerebrospinal fluid, and in embodiments of suchmethods the monitoring comprises serially removing samples of thepatient's blood, measuring the amount of IgG antibodies to JCV in thesamples, and comparing the amount of the antibodies in the samples.

In embodiments the method includes measuring the amount of IgMantibodies to JCV in the samples, and comparing the amount of the IgMand IgG antibodies in the samples. In embodiments the monitoring detectsseroconversion and/or an increasing titer of JCV in the patient's urineand/or blood, and further includes removing a sample of the patient'scerebrospinal fluid when the comparison of the serial urine and/or bloodsamples detect seroconversion and/or an increasing titer of JCV; andtesting the cerebrospinal fluid for the presence of JCV.

In embodiments of the method, the monitoring comprises testing forclinical and/or radiologic symptoms of progressive multifocalleukoencephalopathy. In embodiments the testing for clinical symptomscomprises testing for new or worsening neurological symptoms. Inembodiments the neurological symptoms comprise one or more of centralblindness, mental confusion, personality change, and dyskinesia. Inembodiments the testing for radiologic symptoms comprises performing aGd-enhanced magnetic resonance imaging scan.

In embodiments the method includes, in the presence of indicators ofprogressive multifocal leukoencephalopathy, providing at least onetreatment selected from intravenous immunoglobulin therapy,plasmapheresis, and antiviral therapy. In embodiments the antiviraltherapy comprises the administration of at least one therapeuticallyeffective dose of an antiviral agent selected from cytosine arabinoside(cytarabine), cidofovir, and a serotonin antagonist. In embodiments ofthe method, the serotonin antagonist is a 5HT2a antagonist.

In embodiments of the method the patient is not treated simultaneouslywith natalizumab and an immunosuppressive or antineoplastic agent. Inembodiments the immunosuppressive or antineoplastic agent is selectedfrom one or more of chlorambucil, melphalan, 6-mercaptopurine, thiotepa,ifosfamide, dacarbazine, procarbazine, temozolomide, hexamethylmelamine,doxorubicin, daunarubicin, idarubicin, epirubicin, irinotecan,methotrexate, etoposide, vincristine, vinblastine, vinorelbine,cytarabine, busulfan, amonafide, 5-fluorouracil, topotecan, MUSTARGEN®,bleomycin, lomustine, semustine, mitomycin C, MUTAMYCIN®, cisplatin,carboplatin, oxaliplatin, methotrexate, trimetrexate, raltitrexed,fluorodeoxyuridine, capecitabine, FTORAFUR™, ‘5-ethynyluracil,6-thioguanine, cladribine, pentostatin, teniposide, mitoxantrone,losoxantrone, actinomycin D, vindesine, docetaxel, amifostine,interferon alpha, tamoxafen, medroxyprogesterone, megestrol, raloxifene,letrozole, anastrozole, flutamide, bicalutamide, retinoic acids, arsenictrioxide, rituximab, CAMPATH-1, MYLOTARG®, mycophenolic acid,tacrolimus, glucocorticoids, sulfasalazine, glatiramer, fumarate,laquinimod, FTY-720, interferon tau, daclizumab, infliximab, 1L10,anti-1L2 receptor antibody, anti-IL-12 antibody, anti-1L6 receptorantibody, CDP-571, adalimumab, etanercept, leflunomide, anti-interferongamma antibody, abatacept, fludarabine, cyclophosphamide, azathioprine,cyclosporine, intravenous immunoglobulin, 5-ASA (mesalamine), and aβ-interferon.

In another aspect the invention provides a method of using natalizumabto treat a patient with an inflammatory or autoimmune disease byremoving a sample of blood from the patient; testing the serum or plasmaof the sample for the presence of IgG antibodies to JCV; initiatingtreatment of the patient with natalizumab in the event the sample isnegative for IgG antibodies to JCV; monitoring the patient forindicators of progressive multifocal leukoencephalopathy; anddiscontinuing the administration of natalizumab in the presence ofindicators of progressive multifocal leukoencephalopathy; wherein thetesting and monitoring improve the safety of the treatment. Inembodiments of the method the disease is multiple sclerosis. Inembodiments the multiple sclerosis is selected from relapsing remitting,secondary progressive, primary progressive, and chronic progressivemultiple sclerosis. In embodiments of the method the disease isinflammatory bowel disease or rheumatoid arthritis. In embodiments theinflammatory bowel disease is Crohn's Disease. In embodiments the methodfurther includes testing the serum or plasma of the sample for IgMantibodies to JCV and initiating treatment if the serum or plasma isnegative for both IgG and IgM antibodies to JCV. In embodiments of themethod the monitoring detects JCV in the patient's urine, blood, and/orcerebrospinal fluid. In embodiments of such methods the monitoringcomprises serially removing samples of the patient's blood, measuringthe amount of IgG antibodies to JCV in the samples, and comparing theamount of the antibodies in the samples. In embodiments the monitoringfurther comprises measuring the amount of IgM antibodies to JCV in thesamples, and comparing the amount of the IgM and IgG antibodies in thesamples. In embodiments the monitoring detects seroconversion and/or anincreasing titer of JCV in the patient's urine and/or blood by removinga sample of the patient's cerebrospinal fluid when the comparison of theserial urine and/or blood samples detect seroconversion and/or anincreasing titer of JCV; and testing the cerebrospinal fluid for thepresence of JCV. In embodiments of the method the monitoring comprisestesting for clinical and/or radiologic symptoms of progressivemultifocal leukoencephalopathy. In embodiments the testing for clinicalsymptoms comprises testing for new or worsening neurological symptoms.In embodiments the neurological symptoms comprise one or more of centralblindness, mental confusion, personality change, and dyskinesia. Inembodiments the testing for radiologic symptoms comprises performing aGd-enhanced magnetic resonance imaging scan.

In embodiments, the method further includes, in the presence ofindicators of progressive multifocal leukoencephalopathy, providing atleast one treatment selected from intravenous immunoglobulin therapy,plasmapheresis, and antiviral therapy. In embodiments the antiviraltherapy comprises the administration of at least one therapeuticallyeffective dose of an antiviral agent selected from cytosine arabinoside(cytarabine), cidofovir, and a serotonin antagonist. In embodiments theserotonin antagonist is a 5HT2a antagonist.

In embodiments of the method the patient is not treated simultaneouslywith natalizumab and an immunosuppressive or antineoplastic agent. Inembodiments the immunosuppressive or antineoplastic agent is selectedfrom one or more of chlorambucil, melphalan, 6-mercaptopurine, thiotepa,ifosfamide, dacarbazine, procarbazine, temozolomide, hexamethylmelamine,doxorubicin, daunarubicin, idarubicin, epirubicin, irinotecan,methotrexate, etoposide, vincristine, vinblastine, vinorelbine,cytarabine, busulfan, amonafide, 5-fluorouracil, topotecan, MUSTARGEN®,bleomycin, lomustine, semustine, mitomycin C, MUTAMYCIN®, cisplatin,carboplatin, oxaliplatin, methotrexate, trimetrexate, raltitrexed,fluorodeoxyuridine, capecitabine, FTORAFUR™, 5-ethynyluracil,6-thioguanine, cladribine, pentostatin, teniposide, mitoxantrone,losoxantrone, actinomycin D, vindesine, docetaxel, amifostine,interferon alpha, tamoxafen, medroxyprogesterone, megestrol, raloxifene,letrozole, anastrozole, flutamide, bicalutamide, retinoic acids, arsenictrioxide, rituximab, CAMPATH-1, MYLOTARG®, mycophenolic acid,tacrolimus, glucocorticoids, sulfasalazine, glatiramer, fumarate,laquinimod, FTY-720, interferon tau, daclizumab, infliximab, IL10,anti-IL2 receptor antibody, anti-IL-12 antibody, anti-IL6 receptorantibody, CDP-571, adalimumab, etanercept, leflunomide, anti-interferongamma antibody, abatacept, fludarabine, cyclophosphamide, azathioprine,cyclosporine, intravenous immunoglobulin, 5-ASA (mesalamine), and aβ-interferon.

In another aspect the invention provides a method of administeringnatalizumab to a patient with an inflammatory or autoimmune disease byremoving a sample of blood from the patient; testing the serum or plasmaof the sample for the presence of IgG antibodies to JCV; initiatingtreatment of the patient with natalizumab in the event the sample ispositive for IgG antibodies to JCV; monitoring the patient forindicators of progressive multifocal leukoencephalopathy; anddiscontinuing the administration of natalizumab in the presence ofindicators of progressive multifocal leukoencephalopathy; wherein thetesting and monitoring improves the safety of the treatment. Inembodiments of the method the disease is multiple sclerosis. Inembodiments the multiple sclerosis is selected from relapsing remitting,secondary progressive, primary progressive, and chronic progressivemultiple sclerosis. In embodiments of the method the disease isinflammatory bowel disease or rheumatoid arthritis. In embodiments theinflammatory bowel disease is Crohn's Disease. In embodiments of themethod the monitoring detects JCV in the patient's urine, blood, and/orcerebrospinal fluid. In embodiments the monitoring comprises seriallyremoving samples of the patient's blood, measuring the amount of IgGantibodies to JCV in the samples, and comparing the amount of theantibodies in the samples. In embodiments the monitoring detects anincreasing titer of JCV in the patient's urine and/or blood, and furtherincludes removing a sample of the patient's cerebrospinal fluid when thecomparison of the serial urine and/or blood samples detect an increasingtiter of JCV; and testing the cerebrospinal fluid for the presence ofJCV. In embodiments of the method the monitoring comprises testing forclinical and/or radiologic symptoms of progressive multifocalleukoencephalopathy. In embodiments the testing for clinical symptomscomprises testing for new or worsening neurological symptoms. Inembodiments the neurological symptoms comprise one or more of centralblindness, mental confusion, personality change, and dyskinesia. Inembodiments the testing for radiologic symptoms comprises performing aGd-enhanced magnetic resonance imaging scan.

In embodiments the method further includes, in the presence ofindicators of progressive multifocal leukoencephalopathy, providing atleast one treatment selected from intravenous immunoglobulin therapy,plasmapheresis, and antiviral therapy. In embodiments the antiviraltherapy comprises the administration of at least one therapeuticallyeffective dose of an antiviral agent selected from cytosine arabinoside(cytarabine), cidofovir, and a serotonin antagonist. In embodiments theserotonin antagonist is a 5HT2a antagonist.

In embodiments of the method the patient is not treated simultaneouslywith natalizumab and an immunosuppressive or antineoplastic agent. Inembodiments the immunosuppressive or antineoplastic agent is selectedfrom one or more of chlorambucil, melphalan, 6-mercaptopurine, thiotepa,ifosfamide, dacarbazine, procarbazine, temozolomide, hexamethylmelamine,doxorubicin, daunarubicin, idarubicin, epirubicin, irinotecan,methotrexate, etoposide, vincristine, vinblastine, vinorelbine,cytarabine, busulfan, amonafide, 5-fluorouracil, topotecan, MUSTARGEN®,bleomycin, lomustine, semustine, mitomycin C, MUTAMYCIN®, cisplatin,carboplatin, oxaliplatin, methotrexate, trimetrexate, raltitrexed,fluorodeoxyuridine, capecitabine, FTORAFUR™, 5-ethynyluracil,6-thioguanine, cladribine, pentostatin, teniposide, mitoxantrone,losoxantrone, actinomycin D, vindesine, docetaxel, amifostine,interferon alpha, tamoxafen, medroxyprogesterone, megestrol, raloxifene,letrozole, anastrozole, flutamide, bicalutamide, retinoic acids, arsenictrioxide, rituximab, CAMPATH-1, MYLOTARG®, mycophenolic acid,tacrolimus, glucocorticoids, sulfasalazine, glatiramer, fumarate,laquinimod, FTY-720, interferon tau, daclizumab, infliximab, IL10,anti-IL2 receptor antibody, anti-IL-12 antibody, anti-IL6 receptorantibody, CDP-571, adalimumab, etanercept, leflunomide, anti-interferongamma antibody, abatacept, fludarabine, cyclophosphamide, azathioprine,cyclosporine, intravenous immunoglobulin, 5-ASA (mesalamine), and aβ-interferon.

In another aspect the invention provides a method of using natalizumabto treat a patient with an inflammatory or autoimmune disease byremoving a sample of blood from the patient; testing the sample for thepresence of IgG antibodies to JCV; initiating treatment of the patientwith natalizumab; informing the prescribing physician about the mentaland physical symptoms of progressive multifocal leukoencephalopathy;informing the patient about the mental and physical symptoms ofprogressive multifocal leukoencephalopathy and instructing the patientto report to the physician in the presence of at least one symptom;monitoring the patient for indicators of progressive multifocalleukoencephalopathy; and discontinuing the administration of natalizumabin the presence of indicators of progressive multifocalleukoencephalopathy; wherein the testing, information, and monitoringimprove the safety of the treatment. In embodiments of the method thedisease is multiple sclerosis. In embodiments the multiple sclerosis isselected from relapsing remitting, secondary progressive, primaryprogressive, and chronic progressive multiple sclerosis. In embodimentsof the method the disease is inflammatory bowel disease or rheumatoidarthritis. In embodiments the inflammatory bowel disease is Crohn'sDisease. In embodiments of the method the monitoring detects JCV in thepatient's urine, blood, and/or cerebrospinal fluid. In embodiments themonitoring comprises serially removing samples of the patient's blood,measuring the amount of IgG antibodies to JCV in the samples, andcomparing the amount of the antibodies in the samples. In embodimentsthe monitoring further comprises measuring the amount of IgM antibodiesto JCV in the samples, and comparing the amount of the IgM and IgGantibodies in the samples. In embodiments the monitoring detectsseroconversion and/or an increasing titer of JCV in the patient's urineand/or blood, and further includes removing a sample of the patient'scerebrospinal fluid when the comparison of the serial urine and/or bloodsamples detect seroconversion and/or an increasing titer of JCV; andtesting the cerebrospinal fluid for the presence of JCV.

In embodiments of the method the monitoring comprises testing forclinical and/or radiologic symptoms of progressive multifocalleukoencephalopathy. In embodiments the testing for clinical symptomscomprises testing for new or worsening neurological symptoms. Inembodiments the neurological symptoms comprise one or more of centralblindness, mental confusion, personality change, and dyskinesia. Inembodiments the testing for radiologic symptoms comprises performing aGd-enhanced magnetic resonance imaging scan.

In embodiments the method further includes, in the presence ofindicators of progressive multifocal leukoencephalopathy, providing atleast one treatment selected from intravenous immunoglobulin therapy,plasmapheresis, and antiviral therapy. In embodiments the antiviraltherapy comprises the administration of at least one therapeuticallyeffective dose of an antiviral agent selected from cytosine arabinoside(cytarabine), cidofovir, and a serotonin antagonist. In embodiments theserotonin antagonist is a 5HT2a antagonist.

In embodiments of the method the patient is not treated simultaneouslywith natalizumab and an immunosuppressive or antineoplastic agent. Inembodiments the immunosuppressive or antineoplastic agent is selectedfrom one or more of chlorambucil, melphalan, 6-mercaptopurine, thiotepa,ifosfamide, dacarbazine, procarbazine, temozolomide, hexamethylmelamine,doxorubicin, daunarubicin, idarubicin, epirubicin, irinotecan,methotrexate, etoposide, vincristine, vinblastine, vinorelbine,cytarabine, busulfan, amonafide, 5-fluorouracil, topotecan, MUSTARGEN®,bleomycin, lomustine, semustine, mitomycin C, MUTAMYCIN®, cisplatin,carboplatin, oxaliplatin, methotrexate, trimetrexate, raltitrexed,fluorodeoxyuridine, capecitabine, FTORAFUR™, 5-ethynyluracil,6-thioguanine, cladribine, pentostatin, teniposide, mitoxantrone,losoxantrone, actinomycin D, vindesine, docetaxel, amifostine,interferon alpha, tamoxafen, medroxyprogesterone, megestrol, raloxifene,letrozole, anastrozole, flutamide, bicalutamide, retinoic acids, arsenictrioxide, rituximab, CAMPATH-1, MYLOTARG®, mycophenolic acid,tacrolimus, glucocorticoids, sulfasalazine, glatiramer, fumarate,laquinimod, FTY-720, interferon tau, daclizumab, infliximab, IL10,anti-IL2 receptor antibody, anti-IL-12 antibody, anti-IL6 receptorantibody, CDP-571, adalimumab, etanercept, leflunomide, anti-interferongamma antibody, abatacept, fludarabine, cyclophosphamide, azathioprine,cyclosporine, intravenous immunoglobulin, 5-ASA (mesalamine), and aβ-interferon.

DETAILED DESCRIPTION OF THE INVENTION Brief Description of theEmbodiments Definitions

The terms used herein have their ordinary meanings, as set forth below,and can be further understood in the context of the specification.

A “patient” or “subject,” used interchangeably herein, is a human unlessotherwise indicated.

“Treatment” means any administration or application of remedies fordisease and includes inhibiting the disease, arresting its development,and relieving the disease, for example, by causing regression, orrestoring or repairing a lost, missing, or defective function or bystimulating an inefficient process.

“Natalizumab” is a humanized antibody against VLA-4 as described in U.S.Pat. Nos. 5,840,299 and 6,033,665, which are herein incorporated byreference in their entireties. Also contemplated herein are otherantibodies specific for VLA-4, including, but not limited to,immunoglobulins described in U.S. Pat. Nos. 6,602,503 and 6,551,593, andpublished U. S. Application No. 20020197233 by Relton et al. Theseantibodies can be prepared by the methods disclosed in these documents,by mammalian cell expression systems, and by transgenic animalexpression systems, for example, transgenic goats

A “pharmaceutically effective amount” or “therapeutically effectiveamount,” used interchangeably, is an amount sufficient to cure or atleast partially arrest the symptoms of a disease and/or thecomplications of a disease.

A “serotonin antagonist” is any substance that decreases one or moreeffect of serotonin.

“Seroconversion” is the change of a serologic test from negative topositive, indicating the development of antibodies.

“Titer” is the concentration of an antibody in solution.

Natalizumab

Natalizumab is a humanized IgG₄κ monoclonal antibody directed againstthe α4-integrins α4β1 and α4β7. Studies by Yednock and others have shownthe clinical efficacy of α4-integrin blockade in experimental allergicencephalomyelitis (EAE), an animal model of MS (Yednock et al., Nature1992; 356:63-66 (1992); Baron et al., J. Exp. Med. 177:57-68 (1993);Kent et al., J. Neuroimmunol. 58:1-10 (1995); Brocke et al., Proc. Natl.Acad. Sci. 96:6896-6901 (1999). These data demonstrated that α4-integrinblockade by a bound antibody can prevent leukocyte migration into thebrain and thus support the hypothesis that α4-integrins are a target forMS therapeutics. In addition, these observations support the hypothesisthat blockading leukocyte accumulation in the brain will prevent thelocal destruction of myelin, the insulating sheath covering nervefibers, and neurons, which characterizes MS lesions. Natalizumab is thefirst antibody directed at this target and clinical data demonstrate therelevance of this treatment strategy.

Natalizumab is a member of an emerging class of agents known as theSelective Adhesion Molecule (SAM) Inhibitors. Natalizumab binding toα4β1 (also called VLA-4) and α4β7 integrins inhibits their molecularinteractions with cognate integrin receptors on endothelial cells,VCAM-1 and MAdCAM-1, respectively. By inhibiting these molecularinteractions, natalizumab prevents the recruitment and egress ofleukocytes into sites of inflammation. A further mechanism ofnatalizumab action may be to suppress ongoing inflammatory reactions indiseased tissues by inhibiting the interaction of α4-expressingleukocytes with other ligands in the extracellular matrix (osteopontinand fibronectin) and on parenchymal cells, such as microglial cells(VCAM-1). As such, natalizumab may suppress ongoing inflammatoryactivity at the disease site and inhibit further recruitment of immunecells into inflamed tissues. Thus, treating MS patients with natalizumabmay block entry of mononuclear leukocytes into the CNS and attenuate theinflammatory process that results in demyelination and axonal damage andultimately provide clinical benefit by reducing the number of clinicalrelapses and the progression of disability, including motor, visual, andcognitive function.

Safety of Natalizumab

The safety of natalizumab is demonstrated herein, based on results oftreating 3,919 subjects with natalizumab in clinical trials for MS,Crohn's Disease, and rheumatoid arthritis, resulting in 5,505patient-years of natalizumab exposure. Treatment with natalizumab wasgenerally well tolerated. Eighteen treatment-emergent deaths occurred inthe entire natalizumab program. The adverse events encountered in thetrials, both common and serious, were similar in natalizumab-treatedpatients and controls. Adverse events that led to discontinuation ofnatalizumab occurred in 5.8% of natalizumab-treated MS patients and in4.8% of placebo-treated MS patients, with urticaria being the mostcommon cause of discontinuation in the natalizumab-treated patients(1.2%).

Like other highly active drugs used to treat autoimmune diseases,natalizumab is not without risk. Unfortunately, with the clinicalefficacy of immunomodulatory agents such as natalizumab comes the riskof significant mechanism-based side effects. The risks of medicationsthat modulate immune function in order to treat serious chronic diseaseshave been well recognized over the past several years. Medicines such asthe TNFα antagonists (e.g., infliximab, adalimumab, and etanercept) arepotent modulators of immune function and are approved for numerousserious autoimmune diseases such as rheumatoid arthritis, Crohn'sDisease, psoriasis, psoriatic arthritis, and ankylosing spondylitis.Although very effective, these agents are associated with seriousadverse events, particularly infections that have been associated withsignificant morbidity and mortality.

The invention provides the identification, through detailed safetyanalyses, of PML as a rare, but significant, risk of natalizumabtreatment. In addition, serious non-PML opportunistic infections havebeen observed in natalizumab-treated patients, mostly in Crohn's Diseasepatients in association with concurrent immunosuppressant use or othersignificant co-morbidities. In addition, we have identified patientpopulations in whom the benefit-risk profile is less well defined. Theoccurrence of these infections highlights the need for a comprehensiverisk management program in the post-marketing setting focused onappropriate use conditions and assessment and minimization of the riskof PML and other serious opportunistic infections.

Deaths

Of the eighteen deaths that occurred during the clinical trials, fiveoccurred in the placebo-controlled MS trials, including two in patientswho had received natalizumab and three who had received placebo). Thepatients who received natalizumab died of alcohol intoxication andmetastatic malignant melanoma. The patients who received placebo died ofcardiac arrest, respiratory arrest, and pleural carcinomatosis withseizures. Four deaths occurred in the open-label MS trials, due torespiratory distress, PML, suicide, and seizure due to MS.

Six deaths of natalizumab-treated Crohn's Disease patients were observedin the trials. The exposure to natalizumab was approximately three-foldgreater in these trials than exposure to placebo. The causes of deathwere acute myocardial infarction, acute renal failure, carbon dioxideasphyxiation, PML, pneumocystis carinii pneumonia, and bronchopulmonaryaspergillosis.

Three deaths occurred in the rheumatoid arthritis trials, two innatalizumab-treated patients and one in a patient treated with aplacebo. The natalizumab-treated patients died of hemoptysis withrespiratory failure and end-stage rheumatoid pulmonary disease. Theplacebo-treated patient died of circulatory and respiratoryinsufficiency.

In the MS studies, apart from PML, no other safety signal was apparentfrom the study deaths. In the Crohn's Disease studies, one patient diedfrom PML. Two additional deaths in Crohn's Disease were associated withopportunistic infections, namely, bronchopulmonary aspergillosis andpneumocystis carinii pneumonia. These patients had significantco-morbidities, which may have contributed to the development of theseinfections.

Adverse Events

At least one serious adverse event was encountered by 251 of the 1,617natalizumab-treated MS patients (15.5%) and by 214 of the 1,135placebo-treated patients (18.9%) in the placebo-controlled trial. Themost common serious adverse events, classified by organ systems, werenervous system disorders (5.9% natalizumab, 10.2% placebo). MS relapsecontributed significantly to this incidence (4.7% natalizumab, 9.0%placebo). The second most common serious adverse events were infectionsand infestations (2.4% natalizumab, 2.2% placebo), with appendicitis andurinary tract infection (<1% in both groups) as the most common.

The incidence of hypersensitivity reactions, an event expected to resultfrom treatment with therapeutic proteins, was approximately 4% withserious systemic reactions occurring at an incidence of less than 1%.The reactions tended to occur early in the treatment course, but wereobserved throughout the course of infusion. Although the specificmechanisms of the reactions have not been determined, clinically, thereactions appeared to be typical IgE- or IgG-mediated immediate-typehypersensitivity reactions. All patients recovered without sequalae.

The occurrence of malignancy during natalizumab treatment was uncommon.The incidence of malignancy was balanced between the natalizumab andcontrol groups. The rates of malignancies observed during natalizumabtreatment were within the expected rates per comparison with theexisting cancer registries, such as the National Cancer Institute'sSurveillance Epidemiology and End Results.

Evaluation of PML Cases

Three confirmed cases of PML have been identified, two of which werefatal. Two cases occurred in MS patients and one in a patient withCrohn's Disease. Both MS patients received natalizumab for over twoyears in addition to AVONEX®. The Crohn's Disease patient received eightdoses of natalizumab over an 18-month period and was immunocompromiseddue to chronic azathioprine use as manifested by persistent lymphopenia.All three PML patients presented with subtle clinical changes early intheir disease course that were noted by the patients or their families.

The first patient to contract a fatal case of PML was a 46-year-oldfemale with MS who presented to her neurologist with right-sidedparesthesia and dysesthesia, and right upper extremity clumsiness. MRIbrain scanning demonstrated four non-enhancing T2-hyperintense lesionsbilaterally in the corona radiata. Six weeks later, she presented withnew blurring of the vision in her right eye. Visual acuity was 20/15 inthe left eye and 20/100 in the right. Spinal fluid analysis yielded onewhite blood cell, normal protein and glucose, and no oligoclonal bands.A follow-up MRI brain scan revealed two new subcortical lesions in theright parietal region that were hyperintense on FLAIR imaging andhypointense on T1.

AVONEX® treatment was initiated, but she subsequently suffered threerelapses, the most recent of which involved band-like pain around theabdomen, lower extremity weakness, and spasticity requiring treatmentwith methylprednisolone. Her Expanded Disability Status Scale (EDSS)score in prior to entry into the placebo-controlled MS study, asdescribed in more detail below, was 2.5. She received 30 infusions ofnatalizumab before entering the open-label extension study and receivingan additional seven infusions. She had no exacerbations or suspectedrelapses during her time in the placebo-controlled study. She developedfive new or enlarging T2-hyperintense lesions during the first year ofthe placebo-controlled study and one during the second year. She wasnegative for anti-natalizumab antibodies and her serum concentration ofnatalizumab was similar to the mean of the study populations throughouther participation.

In November 2004, she began to experience motor dysfunction, andcognitive and language difficulties, which progressed to righthemiparesis by the following month. An MRI brain scan performed inDecember 2004 revealed left frontal T2-hyperintensity andT1-hypointensity with extension into the centrum semiovale and coronaradiata without Gd-enhancement. She received two courses of high dosesteroids over the next few months, but continued to decline. Shereceived her last dose of natalizumab on Jan. 18, 2005. She wasreadmitted to the hospital on Feb. 12, 2005 with worsening clinicalstatus. A repeat MRI brain scan in February 2005 showed extension of thelesion seen previously. An extensive work-up over the next week revealedJC viral DNA in the CSF, resulting in the diagnosis of PML. She died onFeb. 24, 2005. Post-mortem examination revealed normal organs withoutevidence of opportunistic infection. The brain examination revealedextensive, severe cavitation mainly in the left hemisphere as well asmultiple non-cavitated, ovoid areas throughout the white matter of bothhemispheres typical of PML, having reactive astrocytes with enlarged,hyperchromatic nuclei (Kleinschmidt-DeMasters and Tyler, N. Engl. J.Med. 353:369-374 (2005)).

The second patient is a 46-year-old male who experienced his firstsymptoms of relapsing/remitting MS in 1983. His past medical history issignificant for auricular zoster, Ramsay-Hunt syndrome, and melanoma.His family history is notable for a sister with MS. He had been treatedwith AVONEX® since 1998, and experienced three-relapses the year beforeenrolling in the placebo-controlled MS study, during which heexperienced no relapses or evidence of progression. He was negative foranti-natalizumab antibodies and his serum concentration of natalizumabwas similar to the mean of the study populations throughout hisparticipation.

In October 2004, his MRI scan showed a small periventricularGd-enhancing lesion on the right and a small right frontal, subcortical,non-enhancing, T2-hyperintense lesion. In November 2004, he exhibitedbehavioral changes followed by hemiparesis and cognitive impairment. Hislast dose of natalizumab was in December 2004. In February 2005, despitetreatment with high dose intravenous methylprednisolone, he continued todeteriorate. A brain MRI scan in February 2005 demonstrated extension ofthe previously identified lesion. He underwent an extensive work-up,including CSF analysis and brain biopsy, which resulted in the diagnosisof PML. Cidofovir treatment was initiated without clinical effect. TheJC viral load decreased in his plasma and CSF over the next few months.This corresponded to further deterioration in his clinical course anddevelopment of Gd-enhancing lesions on MRI, consistent with ImmuneReconstitution Inflammatory Syndrome. He continued to receive treatmentwith cidofovir, and cytarabine was added. Approximately 3 monthsfollowing discontinuation of natalizumab, he began to improve. He isable to converse and can hold high-level conversations about his medicalcourse and treatment, but has significant residual cognitive impairmentwith left hemiparesis and ataxia (Langer-Gould et al., N. Eng. J. Med.353:375-381(2005)).

The final patient was a 60-year-old male with a 28-year history ofCrohn's Disease. Over the course of his illness, he had been treatedwith azathioprine, oral budesonide, corticosteroids, and four doses ofinfliximab. He displayed pre-existing signs of impaired hematopoiesis,predominantly lymphopenia and anemia, since 1996 and receivedazathioprine beginning in 1999. He was enrolled in a Phase 3 study ofnatalizumab in patients with active Crohn's Disease in March 2002 andreceived three doses concomitantly with azathioprine prior to beingrandomized to placebo in a Phase 3 maintenance study. He remained onazathioprine and placebo until November 2002 when azathioprine wasdiscontinued due to refractory pancytopenia. In February 2003, he beganopen-label treatment with natalizumab. He was negative foranti-natalizumab antibodies and his serum concentration of natalizumabwas similar to the mean of the study populations throughout hisparticipation.

In July 2003, one month after his fifth dose of natalizumab, hepresented with a one-week history of cognitive decline. A brain MRI scandemonstrated a large T2-hyperintense lesion in the right frontal lobe,and additional hyperintense lesions in the left frontal and temporallobes that did not enhance with gadolinium. He underwent a partialresection of the lesion, the pathology of which was read at the time asan anaplastic astrocytoma, WHO Grade III. He was treated withcorticosteroids and anticonvulsants, but was too ill for radiationtherapy. Follow-up MRI six weeks after surgery showed tumor extension.He deteriorated clinically and died in December 2003. The case wasreported by the treating physician as a malignant astrocytoma, basedupon the final pathology report. In February, as a result of the oneconfirmed and one-suspected case of PML described above, his case wasreassessed and determined to be PML following consultation with twoindependent neuropathologists with expertise in PML (Van Assche et al.,N. Engl. J. Med. 353:362-368 (2005)).

Clinical trial patients exposed to natalizumab were systematicallyassessed for evidence of incipient PML or any other opportunisticinfection. Patients were evaluated if they had any active neurologicaldeterioration for which PML could not be excluded as a diagnosis, showedMRI abnormalities for which PML could not be ruled out, or their CSF haddetectable JCV DNA titers.

Criteria were established prospectively for the neuroradiologic evidenceand laboratory assays for the diagnosis of PML. A diagnosis of“confirmed PML” was defined by presence of progressive clinical disease,MRI signs typical of PML, detection of JCV DNA in CSF, or pathologicconfirmation. Sufficient evidence to exclude PML was defined as lack ofprogressive neurological disease, MRI lesions not typical of PML orstable over time, or no detectable JCV DNA in the CSF if the MRI wassuspicious. A case was deemed “indeterminate” if there was clinical orMRI suspicion of PML and follow-up clinical, MRI, or CSF data could notbe obtained.

A total of 3,826 eligible study participants (2,248 MS patients, and1,578 Crohn's Disease/rheumatoid arthritis patients) were notified toreport to their treating physician/investigators for an assessment.Investigators were requested to perform the assessment procedure,including medical history, neurological examination, brain MRI, and CSFcollection. Blood samples were also collected for PCR analysis of JCVDNA as an exploratory adjunct. MRI scans were assessed by Central ReaderCenters with expertise in neurological disorders, including the twoCentral Reader Centers for the original Phase 3 MS studies. A consensusguideline was developed prospectively to standardize criteria to helpdistinguish MS white matter abnormalities from those of PML.

In all, 3,389 (89%) study patients with MS, Crohn's Disease, orrheumatoid arthritis were assessed by their treating physician, 3,116 ofwhom had received natalizumab. The remaining 273 patients had receivedplacebo as part of a clinical trial and were included as a controlgroup. Of the 437 that were not assessed, 60 (22 MS patients, 38 Crohn'sDisease/rheumatoid arthritis patients) were lost to follow-up. Amongstthe 3,389 patients who participated, 2,046 were MS study patients, over97% of whom were seen within three months of their last natalizumabdose. Six MS patients were referred for further evaluation. Of theseclinical trial patients, five were referred due to neurologicalworsening and one due to possible PML based on MRI findings. MRI scanreview effectively ruled out the diagnosis of PML in the five patientsreferred based on clinical concern. Repeat MRI and CSF analysis excludedPML in the case referred based on MRI findings.

Of the 1,349 Crohn's Disease/rheumatoid arthritis patients whoparticipated in the safety evaluation, 21% were seen within three monthsof their last dose, 91% within six months. Thirty-five patients wereevaluated, including one due to clinical or neurological symptoms, 32based on suspicious changes on MRI, one due to high plasma JCV copynumber, and one due to an inability to perform MRI in a patient with anormal neurological examination. The higher rate of examination ofCrohn's Disease compared to MS was predominantly driven by the lack ofbaseline MRI scans for comparison in the Crohn's Disease population.Most cases were deemed not to be PML based on review of neurologicalexamination, MRI and, if available, CSF testing. For the ten cases inwhich concern still remained, repeat MRI assessments were performed andall were diagnosed as “not PML” based on lack of clinical progression,lack of MRI progression over two months following the initial MRIleading to referral for evaluation, and in some cases, results of CSFtesting.

MRI scans of the brain with and without Gd-enhancement and a FLAIRsequence were sometimes a useful tool for excluding a diagnosis of PMLin the MS cases. The existence of pre-treatment and on-treatment MRIscans increased specificity and assisted in interpretation of thefollow-up MRI scans obtained at varying time points, especially in thesetting when the patient's neurological condition was worsening. Duringthe safety evaluation process, comparison to previous scan was requiredin approximately 35% percent of MS cases because of the presence oflesions for which PML could not be definitely excluded. After comparisonto a prior scan, the neuroradiologist was able to exclude PML in greaterthan 99% of MS cases.

CSF was available for testing in 396 patients who had been treated forMS or Crohn's Disease with natalizumab. JCV was not detected in any ofthese cases, including 19 patients evaluated based on clinical or MRIcriteria. Samples from 411 patients with MS and other neurologicaldisorders served as CSF and plasma controls and were evaluated incollaboration with the Karolinska Institute and the National Institutesof Health (Yousry et al., N. Engl. J. Med. scheduled for publicationMar. 2, 2006). No detectable JCV was found in these CSF samples,confirming the specificity of the CSF assay for only active cases ofPML. Each of the three patients with confirmed PML had detectable JCVDNA. A previous study had indicated that JCV was found in 11% of thebiological specimens of the 121 MS patients tested (Ferrante et al.,Multiple Sclerosis 4:49-54 (1998).

Plasma was tested for the presence of JCV DNA as an exploratory measure.The entire consenting study population (2,370 patients) was evaluatedusing a high-throughput automated system of DNA extraction and PCRanalysis. In addition, a random subset of samples was assessed using amanual low-throughput method. Although the manual method wasdemonstrated to be an order of magnitude more sensitive than thehigh-throughput system, given the techniques involved, testing usingthis method was only possible in approximately 10% of the overallpopulation (209 patients). Of the 2,370 patients from the safetyevaluation who were tested for JC viremia, only five patients (0.2%) haddetectable JCV DNA, three of whom had never received natalizumab. Inaddition, JCV DNA was not detected in any of the 411 samples from MSpatients naïve to treatment and patients with other neurologicaldiseases. These results were confirmed using the manual extractionmethod. In addition, of the random subset of 209 patients tested by themanual method, an additional five (2.4%) samples had detectable JCV DNA.None of the patients with detectable JCV DNA in their plasma by eithermethod had clinical features or MRI findings suggestive of PML.

Serum samples were available from the three patients with confirmed PMLobtained both before and after diagnosis. Only one patient, the patientwith Crohn's Disease, had detectable JCV DNA in the serum prior to theonset of his symptoms. The other two patients had no detectable JCV DNAdespite being clinically symptomatic for the disease and manifestingchanges on a brain MRI scan. The observations in these groups ofpatients are consistent with the data from the literature demonstratingthat the mere presence of JCV DNA in plasma is neither predictive nordiagnostic of PML.

In summary, the comprehensive safety assessment performed following theidentification of PML in natalizumab-treated patients uncovered noadditional confirmed cases of PML in the over 3,000 patients examined.Nearly all patients who had received natalizumab in recent MS, Crohn'sDisease, and rheumatoid arthritis studies were accounted for during theassessments, making it unlikely that any cases of PML were missed. Theoccurrence of PML was limited to two MS cases and one Crohn's Diseasecase, as originally described. The incidence of PML in subjects treatedwith natalizumab in MS and Crohn's Disease clinical trials is thereforeapproximately 1/1,000 with a 95% confidence interval ranging from 0.2 to2.8/1,000. Plasma testing proved to be neither predictive nor diagnosticof PML, consistent with the published literature (Kitamura et al., J.Infect. Dis. 161:1128-1133 (1990); Tornatore et al., Ann. Neurol.31:454-462 (1992); Dorries et al., Virology 198:59-70 (1994); Agostiniet al., J. Clin. Microbiol. 34:159-164 (1996); Dubois et al., AIDS10:353-358 (1996); Knowles et al., J. Med. Virol. 59:474-479 (1999);Dorries et al., J. Neurovirol. 9 (Suppl 1):81-87 (2003)). Clinical andMRI abnormalities were present in two of the three patients with PMLbefore JCV DNA was detected in the plasma. In addition, JCV DNA wasdetected in plasma in several subjects in the study who had no clinicalor radiographic signs of PML, including three who had never receivednatalizumab. These results suggest that establishing one static level ofplasma JCV is not useful in predicting the likelihood of PML inasymptomatic patients. Physicians and patients should remain vigilantfor signs and symptoms of PML and have a low threshold to suspendtreatment and initiate appropriate diagnostic work-up (MRI, CSFanalysis) in natalizumab-treated patients presenting with newneurological decline.

Consequences of Stopping Therapy

The consequences of stopping natalizumab therapy were carefullyevaluated in a Phase 2 study, which involved 213 patients randomized toreceive six monthly infusions of placebo, 3 mg/kg natalizumab, or 6mg/kg natalizumab. Patients were followed for seven months after thelast infusion. During that time, relapses and other adverse events wererecorded, and MRI scans were performed four months and seven monthsafter the last dose of natalizumab. Comparisons were made between theplacebo group and the two natalizumab dosing groups. As expected, theproportion of patients experiencing relapse, as well as the frequency ofrelapses, rose in the natalizumab group to levels comparable to those inthe placebo group after the cessation of study drug. Moreover, there wasa gradual rise in the proportion of active MRI scans in the natalizumabgroup to levels comparable to that of the placebo group after thecessation of therapy. Thus, the cessation of natalizumab treatmentresulted in loss of efficacy, but there was no evidence of an increasein disease activity beyond that which would have been expected had therebeen no treatment with natalizumab, i.e., no rebound effect wasobserved. Therefore, MS patients who discontinue natalizumab therapy donot have an increased risk for marked increase in disease activity.

Drug Interactions

In a placebo-controlled MS study, the administration of AVONEX® appearedto be associated with an increase in the serum concentrations ofnatalizumab in a small cohort on whom intensive pharmacokinetic samplingwas performed. However, based upon a comparison of the mean post-hocparameter estimates from the population pharmacokinetic analysis,steady-state clearance and half-life values differed between patientsconcurrently taking AVONEX® and natalizumab monotherapy, but only byapproximately 5%, and were not considered clinically significant. Inaddition, natalizumab was well tolerated when administered to 589patients in combination with AVONEX® for up to 120 weeks. It is notablethat the two reports of PML in the MS database occurred in patientsreceiving concomitant AVONEX®. Thus, the risk of PML with natalizumabtreatment may be increased by concomitant treatment with interferon β,though this could have occurred in two patients on combination therapydue to chance alone (p=0.23).

The safety of natalizumab in combination with glatiramer acetate wasevaluated by administering natalizumab over six months to patients whocontinued to receive 20 mg of daily glatiramer acetate. There were nointeractions between glatiramer acetate and natalizumab pharmacokineticsor its α4-integrin receptor saturation. However, this study was ofinsufficient size or duration to establish the long-term safety orefficacy in this population.

Efficacy of Natalizumab

Multiple Sclerosis

MS is a chronic disease of the brain and spinal cord. In temperate zonessuch as the United States, the incidence of MS is approximately 1 to5/100,000 per year (US National MS Society; NMSS), with a US prevalenceestimated at 350,000 to 400,000. It is a disease of young adults,primarily women, with disease onset typically occurring between the agesof 20 and 40. The first clinical manifestations of MS usually take theform of a clinically isolated syndrome affecting the optic nerve (opticneuritis), spinal cord (transverse myelitis), or brainstem/cerebellum(Runmarker and Anderson, Brain 116:117-134 (1993)). Estimates of thenumber of patients who eventually go on to develop MS vary widely, but,in the case of optic neuritis, the presence of MS-like lesions on MRI atthe time of the attack indicates a greater than 80% chance of developingclinically definite MS within 10 years (O'Riordan et al., Brain121:495-503 (1998); Sailer et. al., Neurology 52:599-606 (1999)).

Demyelination and nerve fiber transection is thought to occur whenactivated T lymphocytes cross the blood-brain barrier and initiate aseries of events leading to activation of endothelial cells, recruitmentof additional lymphocytes and monocytes, and release of pro-inflammatorycytokines. MS lesions typically consist of immune cells, demyelinatedaxons, oligodendrocytes attempting remyelination, proliferatingastrocytes, and varying degrees of axonal transection. Cytokines such astumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ)interact with immune cells, amplifying this process. The initiatingevent of the inflammatory cascade is unknown; however, adhesion andtrans-endothelial migration of inflammatory cells from the bloodstreamacross the blood-brain barrier and into the central nervous system (CNS)is thought to be an early and critical step in this process.

Emerging data demonstrate that irreversible axonal loss occurs early inthe course of MS. Because transected axons fail to regenerate in theCNS, early effective treatment aimed at suppressing MS lesion formationis of paramount importance. As early as disease onset, axons aretransected in lesions with active inflammation (Trapp et al., N. Engl.J. Med. 338:278-285 (1998); Bjartmar and Trapp, Curr. Opin. Neurol.14:271-278 (2001); Ferguson et al., Brain 120 (Pt 3):393-399 (1997)).The degree of demyelination is related to the degree of inflammation andthe exposure of demyelinated axons to the inflammatory environment, aswell as non-inflammatory mediators (Trapp et al., N. Engl. J. Med.;338:278-285 (1998); Kornek et al., Am. J. Pathol. 157:267-276 (2000);Bitsch et al., Brain 123:1174-1183 (2000)). There is also destruction ofoligodendrocytes with impaired remyelination in demyelinating lesions(Peterson et al., J. Neuropathy Exp. Neurol. 61:539-546 (2002); Chang etal., J. Neurovirol. 8:447-451 (2002)). The loss of oligodendrocytesleads to a reduction in the capacity to remyelinate and may result inthe loss of trophic factors that support neurons and axons (Bjartmar etal., J. Neurocytol. 28:383-395 (1999)).

The typical inflammatory lesions of MS can occur throughout the CNS, butcertain sites seem particularly vulnerable, such as the optic nerve,brainstem, spinal cord, and periventricular regions of the cerebrum. Itis the resulting loss of myelin and nerve fibers in these areas thatleads to impaired neuronal conduction and symptoms such as weakness,sensory loss, visual loss, double vision, and imbalance. In relapsingremitting MS, these episodes of demyelination typically result inseveral weeks of neurological dysfunction followed by partial or fullrecovery. However, more severe attacks may result in permanent deficits.The recurrent attacks over time lead to accumulating physical disabilityand cognitive decline.

A number of measures, including clinical measures, those based on MRIscans, and those based on quality of life, can be used to assess aproduct's efficacy in treating MS. The Expanded Disability Status Scale(EDSS) is an extensively used tool for tracking the course of disabilityin MS. It classifies the most common MS-associated neurologicalimpairments into disability levels ranging from 0 to 10, with eachsuccessive step describing a worsening of disease. In the lower range ofthe EDSS scale, disease progression is primarily defined by increasinglevels of disability in specific functional systems measured duringneurological examination. Scores of 1.0 through 3.5 describe mild tomoderate disability in the functional systems. Higher scores, in therange of 4.0 and above indicate increasingly severe disability thataffects ambulation, including the need for assistive devices such as acane (an EDSS of 6.0), a walker (an EDSS of 6.5), or a wheelchair (anEDSS of 7.0). Scores higher than 7.0 classify patients confined to bed.

The MS Functional Composite (MSFC) (Whitaker et al., Multiple Sclerosis1:37-47 (1995)) is also used to assess efficacy. Unlike traditional MSclinical outcome measures that are derived from the standardneurological examination, the MSFC is based on quantitative tests of legfunction/ambulation (the Timed 25-Foot Walk), arm function (theNine-Hole Peg Test), and cognitive function (the Paced Auditory SerialAddition Test (PASAT 3)) which expand upon the measurements of the EDSSand assess effects in clinical dimensions not well captured by thisscale.

MRI is another tool for assessing efficacy in treating MS and can beused alone or to support clinical data to assess therapeutic effects onrelapse and disability endpoints. MRI is a sensitive tool for monitoringdisease activity, detecting approximately five to ten times more diseaseactivity in both relapsing remitting MS and secondary progressive MSpatients than is clinically apparent (Isaac et al., Neurology38:1511-1515 (1988); Willoughby et al., Ann. Neurol. 25:43-44 (1989);Khoury et al., Neurology 44:2120-2124 (1994); Thompson et al., Ann.Neurol. 9:53-62 (1991); Thompson et al., Neurology 42:60-63 (1992)).T2-weighted sequences in MS patients detect new areas of acutedemyelination, as well as more chronic areas of demyelination andgliosis. For this reason; T2-weighted MRI is a good technique formonitoring the accumulation of lesions over time, either as a count ofactive lesions or a change in the total volume of such lesions.

Infusion of gadolinium-diethylenetriamine pentaacetic acid (Gd-DPTA)during acquisition of T1-weighted sequences allows for visualization ofblood-brain barrier breakdown secondary to the inflammationcharacteristic of acute MS lesions. The evidence to date suggests thatgadolinium (Gd)-enhancement is a useful marker of disease activity thatcorrelates with clinical relapse (Molyneux et al., Ann. Neurol.43:332-339 (1998); Kappos et al., Lancet 353:964-969 (1999); McFarlandet al., Multiple Sclerosis 8:40-51 (2002)).

New hypointense lesions on T1-weighted sequences in MS patientscorrespond either with inflammatory Gd-enhancing lesions (comprisingedema, demyelination, axonal loss, or combinations of these pathologies)(Bruck et al., Ann. Neurol. 42:783-793 (1997)) or as chronic lesionswith considerable axonal loss. Approximately half of the acute T1hypointensities on MRI will evolve into chronic “T1 black holes,” whichcorrelate with disability progression (Simon et al., Neurology55:185-192 (2000)).

As described in more detail in Example 1, two Phase 3 studies wereconducted to study the effect of two years of treatment withnatalizumab. One of the studies used natalizumab alone (the monotherapystudy) and the other used natalizumab in combination with AVONEX® (theadd-on therapy study). Both these Phase 3 studies were designed with twosets of primary and secondary endpoints. The primary and secondaryendpoints were selected to measure the effects of natalizumab on theinflammatory aspects of the disease after a mean of one year offollow-up in each study (900 patient-years of observation in themonotherapy study; 1,200 patient-years in the add-on therapy study).

The primary endpoint of these studies was the annualized rate ofclinical relapses. Two of the secondary endpoints were two supportingMRI measures of inflammatory disease activity, namely, the mean numberof new or newly enlarging T2-hyperintense lesions (measuring lesionaccumulation over time) and the mean number of Gd-enhancing lesions(measuring acute disease activity), as ranked in order of importance.The proportion of patients remaining relapse-free provided a thirdsecondary endpoint.

Another series of endpoints was assessed at the conclusion of each studyfollowing two years of natalizumab treatment. The endpoints for thisfinal analysis were selected to determine natalizumab's effects onmeasures associated with MS disease progression. The primary endpoint attwo years was the time until onset of sustained progression ofdisability, as measured by changes in EDSS scores. Similar to theone-year analysis, the secondary endpoints were additional MRI andclinical measures that would support the primary analysis. The secondaryendpoints at two years, ranked in order of importance, were the rate ofMS relapses (to confirm one-year relapse observations), the mean volumeof T2-hyperintense lesions (a measure of overall MS disease burden), themean number of T1-hypointense lesions (a measure of axonal loss), andprogression of disability as determined by changes in the MSFC (toconfirm and expand upon disability effects as measured by the EDSS).

Given two primary endpoints at two different time points (annualizedrelapse rate at one year, time to disability progression at two years),the Hochberg procedure for multiple comparisons (Hochberg, Biometrika75:800-802 (1988)) was used to evaluate the primary endpoint. Each setof secondary endpoints was prioritized in order of importance as listedabove. A closed testing procedure was used for each set, such that ifstatistical significance was not achieved for an endpoint within a set,all endpoints(s) of a lower rank in that set were not consideredstatistically significant. Analyses of tertiary endpoints did notinclude adjustments for multiple comparisons.

Monotherapy with Natalizumab

These results of the monotherapy study indicated that natalizumab is aneffective treatment as monotherapy for relapsing remitting MS.Natalizumab treatment resulted in significant effects on relapse rates,disability progression, and all MRI measures, the primary and secondaryendpoints of the study. Analysis of Kaplan-Meier curves indicate thatthe impact on relapse rates and disability progression was apparentearly after treatment initiation, and was sustained throughout thetreatment period with patient groups continuing to diverge at the finaltime point. Further, these findings were consistent across subgroups.Additional positive effects were seen on measures of relapse severityand quality of life.

MS patients treated with natalizumab alone had a 42% lower risk of theirdisability progressing compared to placebo, as measured by changes onthe EDSS, the primary endpoint of the study at two years (p<0.001). Thepercentage of patients estimated to progress was 17% and 0.29% withnatalizumab and placebo, respectively. In addition to the EDSS,natalizumab had significant effects on all relapse endpoints studiedover two years, including a 68% reduction in the annualized relapse ratecompared to placebo, with 67% of natalizumab-treated patients remainingrelapse-free, compared to 41% of patients on placebo. The MRI scanssupported these clinically-observed effects. Also, natalizumab treatmentimproved the patients' quality of life, as measured by the physical andmental components of the SF-36. All these effects were consistent andsignificant across subgroups defined by baseline demographics anddisease activity.

Combination Therapy of Natalizumab and AVONEX®

A significant number of patients who receive the currently approvedtherapies continue to experience disease activity, as measured bothclinically and by MRI. This is an expected outcome of these partiallyeffective approved medications, each of which leads to an approximately30% reduction in relapse rate (IFNB MS Study Group, Neurology 43:655-661(1993); Jacobs et al., Ann. Neurol. 39:285-289 (1996); PRISMS StudyGroup, Lancet 352:1498-1504 (1998); Johnson et al., Neurology45:1268-1276 (1995)). Data from the Phase 3 trials of β-interferon forthe treatment of MS show that 62% to 75% of patients experienced atleast one relapse during these two-year trials despite interferontreatment IFNB MS Study Group, Neurology 43:655-661 (1993); Jacobs etal., Ann. Neurol. 39:285-289 (1996); PRISMS Study Group, Lancet352:1498-1504 (1998)). Similarly, 66% of subjects in the Phase 3 MStrial of glatiramer acetate experienced at least one relapse during the2-year period, a number that was not significantly different fromplacebo (Johnson et al., Neurology 45:1268-1276 (1995)). Although avariety of therapeutic strategies are currently in use in clinicalpractice to manage breakthrough disease while on treatment (e.g.,switching therapy, changing dose and frequency of interferon,combination therapy), these practices are largely empirical as there areno randomized, controlled trials to assess the efficacy of theseapproaches.

The add-on therapy study was designed to evaluate the efficacy ofnatalizumab against active control for patients breaking through AVONEX®monotherapy. The choice of β-interferon was supported by available dataon the proposed mechanisms of action of the available drugs. Asdiscussed above, natalizumab has a well-defined mechanism of action,specifically targeting cellular adhesion and trans-endothelial migrationvia α4-integrins. Although the exact mechanism by which interferon-βexerts efficacy in MS is not known, interferon-β induces a large numberof cellular processes involved in cytokine secretion and cellularphenotype changes. Interferon-β down regulates interferon-γ induced MHCclass II molecule production, decreases secretion of TH1pro-inflammatory cytokines (TNF-α, IL-2 and interferon-γ) and increasessecretion of TH2 anti-inflammatory cytokines (IL-4 and IL-10) (Rep etal., J. Neuroimmunol. 67:111-118 (1996); Kozovska et al., Neurology53:1692-1697 (1999); Rudick et al., Neurology 50:1266-1272 (1998)). Inaddition, interferon-β may affect leukocyte trafficking throughsuppression of the chemokines RANTES and MIP-1α, as well as theirreceptor CCR5 (Zang et al., J. Neuroimmunol. 112:174-180 (2001)). Thereis, therefore, scientific rationale to expect that the blockade ofα4-integrins by natalizumab, when added to interferon-β, may have anadditive or synergistic effect when added to interferon-β alone.

Natalizumab was also proven efficacious when used to treat patientsconcurrently receiving treatment with AVONEX®. Prior to receivingnatalizumab, these patients were experiencing disease activity despiteactive treatment. Thus, AVONEX® served as an active control. The studydemonstrated that natalizumab, when added to AVONEX®, resulted in a 24%reduction in the risk of disability progression, as measured by changeson the EDSS (p=0.024). The percentage of patients estimated to progresswas 23% with natalizumab plus AVONEX® as compared with 29% on AVONEX®alone.

Natalizumab had significant effects on all relapse endpoints examined,when compared to AVONEX® over two years, including a 55% reduction inthe annualized relapse rate, with 54% of natalizumab-treated patientsrelapse-free compared to 32% of patients on AVONEX®. The MRI scanssupported these clinically-observed effects. Also, natalizumab, whencompared to AVONEX® therapy alone, improved the patients' quality oflife, as measured by the physical components of the SF-36, with a trendon the mental component. All these effects were consistent andsignificant across subgroups defined by baseline demographics anddisease activity.

Progressive Multifocal Leukoencephalopathy

PML is an infectious disease of the central nervous system caused by JCVinfection of oligodendrocytes. JCV is a human polyoma virus that isbelieved to infect the majority of healthy individuals at an early age.The seroprevalence of anti-JCV antibodies in healthy individuals hasbeen estimated to range from 20% to 80% depending upon the testingmethodology (Knowles et al., J. Med. Virol. 71:115-123 (2003)); Knowlesand Sasnauskas, J. Virol. Methods. 109:47-54 (2003)).

PML occurs predominantly in immunocompromised individuals with anage-adjusted death rate due to PML of 3.3 per million persons (in 1994),89% of whom were AIDS patients (Holman et al., Neuroepidemiol.17:303-309 (1998)). However, rare PML cases have also been reported inpatients with autoimmune disorders who received immunosuppressivetherapy; among these, three patients with rheumatoid arthritis(Sponzilli et al., Neurology 25:664-668 (1975); Rankin et al., J.Rheumatol 22:777-79 (1995); Durez et al., Arthritis Rheum. 46 (9S):536(2002)), one of whom was treated with tumor necrosis factor (TNF)antagonist (Durez et al., Arthritis Rheum. 46 (9S):536 (2002)). Therewas also a report of PML in a Crohn's Disease patient, but theconcomitant treatments were not specified (Garrels et al., Am. J.Neuroradiol. 17:597-600 (1996)).

The pathology of PML is distinctive and comprises multiple foci ofdemyelination of varying size from pinpoint lesions to areas of severalcentimeters. The lesions may occur anywhere but are usually in thecerebral hemispheres, less often in the cerebellum and brain stem andrarely in the spinal cord. The oligodendrocytes in the peripheral zonesurrounding an area of demyelination are grossly abnormal. The nuclei ofabnormal oligodendrocytes are packed with JC virions. Typically, PMLevolves gradually, with impairment of mental function and disturbance ofspeech and vision. Movement may also be affected. The disease thenprogresses rapidly and the patient is severely disabled, eventuallybecoming demented, blind, and paralyzed; coma and death follow.

The presence of JCV in the blood and urine of PML patients and healthy,immunocompetent individuals has been described (Kitamura et al., J.Infect. Dis. 161:1128-1133 (1990); Tornatore et al., Ann. Neurol.31:454-462 (1992); Dorries et al., Virology 198:59-70 (1994); Sundsfjordet al., J. Infect. Dis. 169:485-490 (1994); Agostini et al., J. Clin.Microbiol. 34:159-164 (1996); Dubois et al., AIDS 10:353-358 (1996);Knowles et al., J. Med. Virol. 59:474-479 (1999); Dorries et al., J.Neurovirol. 9(Suppl 1):81-87 (2003)). These findings are neitherpredictive nor diagnostic of PML in these patients; thus therelationship of blood or urine viral load to PML is unclear.

The clinical presentation of PML is largely dependent upon the size anddistribution of the white matter lesions that develop as a result ofviral infection, demyelination, and glial cell lysis. However, clinicalfeatures of the presentation help differentiate it from thedemyelination associated with MS. In contrast to MS, PML involvement ofthe spinal cord or optic nerves is rare. Instead, about one-third ofpatients will present with visual field loss or cortical blindness withanother third presenting with altered mentation or behavior changes(Dworkin et al., Curr. Clin. Top. Infect. Dis. 22:181-195 (2002)). Alsounlike MS, hemiparesis is a common presenting symptom. These symptomsare typically subacute in onset and follow a slowly progressive course.Often, patients and their families are the first to notice the onset ofPML through changes in the ability to perform routine activities ofdaily living, even prior to presentation with changes on neurologicalexamination.

MRI is a sensitive tool for the detection of PML lesions in the settingof clinical signs or symptoms, although it may lack specificity. TypicalMS lesions, demyelination from other causes (e.g., encephalomyelitis,HIV encephalopathy), gliosis, and edema can often have an appearancesimilar to early PML lesions. However, as shown in Table 1, there arefeatures of PML lesions that help differentiate them from otheretiologies (Post et al., Am. J. Neuroradiol. 20:1896-1906 (1999); Yousryet al. N. Engl. J. Med. in press (2006); (Berger et al., Ann. Neurol.44:341-349 (1998); Hoffmann et al., J. Neurol. Neurosurg. Psychiatry74:1142-1144 (2003); Langer-Gould et al., N. Engl. J. Med. 353:375-381(2005)).

TABLE 1 Differential Diagnosis of MS and PML MS PML Location of newlesions Mostly focal, may affect entire brain and Diffuse, mainly,sub-cortical, rarely spinal cord, in white and possibly grayperiventricular, almost exclusively in matter; white matter, althoughoccasional extension to gray matter seen; Posterior fossa lesions rarelyseen Posterior fossa frequently involved (cerebellum) Borders Sharpedges, shapes mostly round or Ill-defined edges, infiltrating, irregularin finger-like (especially periventricular), shape, confined to whitematter, sparing confluent with other single lesions, U- gray matter,pushing against cortex, fibers may be involved U-fibers destroyed Modeof extension Focal, enlarging of lesions within Diffuse, asymmetrical,extending days/weeks, later decreasing in size within homogeneously, noconfluence with other months lesions, defined to white matter tracks,sparing cortex, continuous progression Mass effect Acute lesions mayshow some mass effect No mass effect even in large lesions (but processis slightly pushing against cortex) T2-weighted sequence Acute lesions:hyperintense center, Diffuse hyperintense, slightly increased isointensering, discrete hyperintensity intensity of newly involved areas outsidering structure; compared to old areas, little irregular.Sub-acute/chronic lesions: hyperintense, no signal intensity of lesionsring structure T1-weighted sequence Acute lesions: densely hypointense(large Slightly hypointense from the onset, lesion) or isointense (smalllesion), signal intensity decreasing over time and increasing signalintensity over time in along the affected area, no reversion of 80%,decreasing signal intensity (axonal signal intensity loss) in about 20%Flair sequence Hyperintense, sharply delineated Hyperintensity moreobvious, true extension of abnormality more clearly visible than inT2-weighted images Enhancement Acute lesions: dense homogeneous Usuallyno enhancement even in large enhancement, sharp edges lesions, in HIV+patients some peripheral Sub-acute lesions: ring-enhancement enhancementpossible, especially under Chronic lesions: no enhancement therapyAtrophy Focal atrophy possible due to focal white No focal atrophy sinceextending matter degeneration, no progression pathological process isslightly pushing against cortex (extension of tissue)

MRI analysis can provide a differential diagnosis of MS and PML inpatients receiving natalizumab. Patients suspected of PML demonstratethe presence of multifocal, asymmetric, white-matter lesions reflectiveof demyelination by MRI. T₂-weighted and fluid-attenuated inversionrecovery (FLAIR) MRI reveals hyperintense lesions throughout thesupratentorial subcortical white matter (Post et al., Am. J.Neuroradiol. 20:1896-1906 (1999)). White matter lesions of PML aretypically not surrounded by edema, do not produce a mass effect, and donot enhance in the presence of gadolinium contrast material (Post etal., Am. J. Neuroradiol. 20:1896-1906 (1999)). However, hyperintenseT₂-weighted and FLAIR images are not specific for demyelination and mayrepresent gliosis or edema. Other demyelinating, encephalopathic orischemic processes such as MS, postviral encephalitis, HIVencephalopathy and infarction, may demonstrate similar non-specificimaging features (Olsen et al., Radiology 169:445-448 (1988), Hurley etal., J. Neuropsychiatry Clin. Neurosci. 15:1-6 (2003)). The location oflesions and their morphological characteristics, the absence or anatypical presence of gadolinium enhancement on T₁-weighted images, andthe implementation of magnetization transfer MRI may also helpdifferentiate the demyelination of PML from other demyelinatingprocesses, edema or gliosis (Ernst et al., Radiology 210:439-543 (1999);Hurley et al., J. Neuropsychiatry Clin. Neurosci. 15:1-6 (2003)).

The clinical diagnosis of PML is confirmed by histological andvirological examination of brain material obtained by brain biopsy or atpostmortem. Before a biopsy is done, both serum and CSF should beexamined for antibodies against JCV. A positive result will not confirmPML, but a negative result makes the diagnosis of PML very unlikely. Itis rare to detect antibodies against JC in the CSF, and when they aredetected, it is suggestive of active multiplication of JCV within theCNS. The brain biopsy or autopsy material can be examined by electronmicroscopy or immunohistologic electron microscopy. The specimen canalso be examined directly for JCV antigen by immunofluorescence orimmunoperoxidase staining. Viral isolation of JCV has been reported tobe difficult, but may be attempted from primary human fetal glial cells.The presence of the virus in culture is confirmed by electronmicroscopy, immunofluorescence, or hemagglutination.

PCR analysis of the CSF for JC viral DNA is a highly sensitive andspecific test for the diagnosis of PML. The specificity of this testapproaches 100%, with a sensitivity ranging from 60% to 90% (Henson etal., Neurology 41:1967-1971 (1991); Gibson et al., J. Med. Virol.39:278-281 (1993); Weber et al., AIDS 8:49-57 (1994a); Weber et al. J.Infect. Dis. 169:1138-1141 (1994b); Vago et al., J. Acquir. Imm. Defic.Syndr. Hum. Retrovirol. 12:139-146 (1996)). In cases with a highclinical suspicion of PML and negative CSF results, repeat testing oftenleads to detection of JC viral DNA. As such, PCR analysis of the CSF forJC viral DNA has grown to be the preferred method to confirm thediagnosis of PML.

Untreated, PML patients have a mortality rate of 30% to 50% during thefirst three months (Koralnik, Curr. Opt. Neurol. 17:365-370 (2004)).Prior to the introduction of highly active antiretroviral treatment(HAART) for HIV, about 10% of patients with PML survived for longer thanone year. However, since the advent of HAART, about 50% of patients withPML survive for longer than one year due to restoration of immunefunction as CD4 counts increased as a result of immune reconstitutioninflammatory syndrome (Geschwind et al., J. Neurovirol. 7:353-357(2001); Berger et al., Ann. Neurol. 44:341-349 (1998); Clifford et al.,Neurology 52:623-625 (1999); Tantisiriwat et al., Clin. Infect. Dis.28:1152-1154 (1999)).

Currently, there is no established drug treatment for PML. Variousmedications have been tested, including acyclovir, idoxuridine,vidarabine, amantadine, adenine arabinoside, cytosine arabinoside(cytarabine), cidofovir, interferon α, interleukin-2 (IL-2), zidovudine,camptothecin, and topotecan (Koralnik, Curr. Opt. Neurol. 17:365-370(2004); Dworkin et al., Curr. Clin. Top. Infect. Dis. 22:181-195 (2002);Seth et al., J. Neurovirol. 9:236-246 (2003); Collazos, CNS Drugs17:869-887 (2003); Mamidi et al., J. Neurovirol. 8:158-167 (2002);Przepiorka et al., Bone Marrow Transplant; 20:983-987 (1997); Redingtonet al., Arch. Neurol. 59:712-718 (2002); Padgett et al., Prog. Clin.Biol. Res. 105:107-117 (1983)). However, the survival of patients withPML appears to be best correlated with immune reconstitution. Intransplant patients with PML, early dosage reduction or/anddiscontinuation of immunosuppressive therapy was associated withfavorable clinical outcome after PML diagnosis (Crowder et al., Am. J.Transplant 5:1151-1158 (2005); Shitrit et al., Transpl. Int. 17:658-665(2005)).

JC Virus (JCV)

JCV is a member of the class of human polyomavirus, which belong to thePapovaviridae family of small, non-enveloped viruses with a closed,circular double DNA-stranded genome. Polyomaviruses can be distinguishedfrom papillomaviruses by virtue of their smaller virion size anddifferent genomic size and organization. Polyomaviruses are ubiquitousin nature and can be isolated from a number of species. JCV was firstisolated from the brain tissue of a patient with progressive multifocalleukoencephalopathy (PML). JCV shares 35% nucleotide sequence homologywith the BK human polyomavirus (BKV), which was isolated from the urineof a renal transplant patient with postoperative ureteral stenosis. BKVand JCV each’ share 70% homology with SV40. The two are notserologically cross-reactive and serologic tests for antibodies are ableto distinguish between BKV and JCV (Demeter, in Mandell et al., eds.,Mandell, Douglas and Bennett's Principles and Practice of InfectiousDiseases, 4th edition, Vol. 2. New York, N.Y.: Churchill Livingstone;1995:1400-1406).

JCV infection is usually sub-clinical, is almost universal, occurs inchildhood, and persists for life. It is estimated that 60-80% of adultsin Europe and the United States have antibodies to JCV and that 50% ofyoung adults in the age range of 30-39 years have been infected withJCV. JCV and BKV are believed to circulate independently. It has beenproposed that JCV establishes latent infections in the kidney and/or theCNS after a primary infection (Demeter, in Mandell et al., eds.,Mandell, Douglas and Bennett's Principles and Practice of InfectiousDiseases, 4th edition, Vol. 2. New York, N.Y.: Churchill Livingstone;1995:1400-1406). During immunosuppression, it has been postulated thatlatent JCV is reactivated in the kidney, which may lead to viruria.While viruria may have some predictive value for PML, since it does notoccur in the majority of PML cases, measuring JCV in the urine alone isnot sufficient to diagnose JCV.

When JCV travels through the bloodstream to the brain, it may attackmyelin-producing cells. The resulting brain infection producesneurological symptoms which may include ataxia, loss of cognitivefunction, visual loss, changes in balance and coordination, and loss ofsensation. Death commonly occurs within two years following diagnosis.

No specific antiviral therapy that has been proven effective for JCV,and current treatment of immunocompromised patients is primarilysupportive and intended to reduce immunosuppression. Cidofovir iscurrently being studied as a treatment option for transplant patients,and cytarabine can be used in the treatment of PML, although there iscurrently conflicting data regarding the efficacy of the latter(Demeter, in Mandell et al., eds., Mandell, Douglas and Bennett'sPrinciples and Practice of Infectious Diseases, 4th edition, Vol. 2. NewYork, N.Y.: Churchill Livingstone; 1995:1400-1406; Salmaggi, Neurol.Sci. 22:17-20 (2001)).

The cellular receptor for JCV has been reported to be the serotonin5HT2(A) receptor (Elphick et al., Science 306:1380-1383 (2004)). Invitro, the antipsychotic medications chlorpromazine and clozapine wereshown to block the serotonin 5HT2(A) receptor and to block JCV cellentry. Unfortunately, however, chlorpromazine and clozapine have suchsignificant side effects and toxicities, e.g., extrapyramidal symptomsand the possibility of bone marrow dyscrasias that they may beproblematic to use clinically. The invention provides that neweratypical antipsychotics, such as ziprasidone, risperidone, andolanzapine—medicines with much better side effect and toxicity profilesthan the older antipsychotics—are significantly more potent 5HT2(A)receptor antagonists in vitro than chlorpromazine and clozapine.

A wide variety of serological tests are available to detect JCV, e.g.,complement-fixation (CFT), haemagglutination-inhibition (HAI),enzyme-linked immunoassay (EIA), radioimmunoassay (RIA), particleagglutination, immunofluorescence (IF), single radial hemolysis, andWestern blot. The sensitivity and specificity varies greatly betweendifferent techniques. Most techniques will detect all classes ofantibody, whereas some assays e.g., RIA, EIA, and IF can be designed todetect one specific class, for example, IgM, IgG, or IgA.

Patient Selection Based on Safety and Efficacy

Appropriate patient selection helps maximize the benefit-risk profile ofnatalizumab. Natalizumab has demonstrated efficacy in treatment-naïvepatients with mild to moderate disability (EDSS 0 to 5.0) with recentclinical disease activity (for example, one relapse in the year prior tostudy entry). It has also demonstrated efficacy in patients with mild tomoderate disability with continuing disease activity despite treatmentwith β-interferon (for example, one relapse in the year prior to studyentry, while receiving AVONEX®).

The benefit/risk ratio is altered in certain other patient populations.Patients without evidence of relapsing disease, that is, withoutevidence of inflammatory activity clinically or by MRI, such as thosewith relatively “benign” inactive disease, or chronic-progressive formsof MS, were excluded from the Phase 3 trials, thus, natalizumab has notbeen completely evaluated in these cohorts. The benefit-risk is alsoaltered in patients with a single clinical event without featuressuggestive of MS.

Patients who are clinically stable on current therapy also have analtered benefit/risk ratio. If safety or tolerability concerns exist onthe current treatment, or imaging studies indicate active inflammatorysub-clinical disease, natalizumab treatment would be appropriate. Inconsidering the benefit-risk ratio, it should be considered whether thepatient has previously suffered a hypersensitivity reaction or developedpersistent antibodies to natalizumab. Re-dosing of natalizumab followinga hypersensitivity reaction was not assessed in Phase 3 trials.Persistent antibodies against natalizumab lead to a loss of efficacy andan increase in infusion-related side effects. Patients who areimmunocompromised from any cause, including use of immunosuppressantmedications have an independent risk factor for PML and otheropportunistic infections and should not receive natalizumab.

Another criteria for patient selection is a pre-infusion checklist usedby the infusion nurse to facilitate early detection of PML and minimizeinappropriate use of natalizumab. The checklist prompts the nurse to askthe patient about continuously worsening neurological symptoms that havepersisted over several days, e.g., new or sudden decline in thinking,eyesight, balance, or strength. If a patient reports having any symptomsdescribed by the checklist, the nurse is instructed not to administernatalizumab and to refer the patient to his or her physician.

This checklist also ascertains that the patient will be receivingnatalizumab for the treatment of relapsing MS, has never been diagnosedwith PML, and is not currently experiencing any continuously worseningsymptoms that have persisted over several days. It further ascertainsthat the patient is not known to be suffering from HIV or a hematologicmalignancy, nor has had an organ transplant. It confirms that thepatient is not currently receiving treatment with an anti-neoplastic,immunomodulatory, or immunosuppressive agent and that the patient hasread the natalizumab patient information leaflet, which is furtherdescribed in Example 2.

Methods of Treatment

Pharmaceutical compositions of natalizumab will be administeredintravenously. Pharmaceutical compositions of natalizumab are providedat a dose from approximately 1 to 5 mg antibody per kilogram of bodyweight. In an embodiment, a standard dose of 300 mg natalizumab dilutedwith 100 ml 0.9% sodium chloride is injected intravenously once everyfour weeks. The dose maybe repeated at intervals from two to eightweeks. For example, a treatment regimen may comprise 3 mg antibody perkilogram of body weight repeated at approximately a four week interval.Intermittent, e.g., monthly, intravenous administration may be viewed asdesirable by patients deterred by daily, every-other-day, or weeklyself-injection.

Informing Patients and Caregivers

In the US, patients with MS receive medical treatment by a relativelysmall group of physicians, primarily neurologists. Approximately 6,000physicians treat 90% of patients with MS. This is in contrast to 170,000family practitioners that treat primary care diseases in the US. Adedicated force of physicians and sales representatives can interactwith neurologists and other healthcare professionals who care forpatients with MS. Consequently, nearly all physicians who will prescribenatalizumab can readily be contacted.

Because PML is a disease of the central nervous system, the targetedprescribers of natalizumab are also the best-qualified physicians todiagnose and manage PML. Neurologists have the expertise to monitorsubjects for signs and symptoms indicative of PML and select appropriatediagnostic tests to diagnose a patient with PML.

Also, patients with MS are knowledgeable about their treatment options.They are generally a young and highly-motivated. In a recent survey, 94%to 99% of patients with MS were aware of their treatment options,including β-interferons and glatiramer acetate (Biogen Idec). During theperiod when natalizumab was available commercially, 79% of patients withMS were aware of the introduction of natalizumab treatment. Also,feedback from patients with MS indicated that the risk of PML withnatalizumab has been broadly disseminated in the MS community. Thus, thetargeted patient population is likely to want to learn more about therisks of PML with natalizumab.

Accordingly, the invention provides for informing the prescribingphysician and the patient about the mental and physical symptoms ofprogressive multifocal leukoencephalopathy and instructing the patientto report to the physician in the presence of at least one symptom.These informational efforts will provide relapsing MS patients and theirphysicians with the information they need to make informed benefit-riskdecisions about the use of this highly effective therapy, while activelymanaging recognized risks. The invention also provides informationaltools for patients and physicians to promote informed benefit-riskdecisions, to ensure appropriate use of natalizumab, and to reinforcethe importance of early detection of PML through clinical vigilance. Forexample, the invention provides protocols for informing physicians andpatients of the risks of natalizumab treatment and for activelyassessing and managing these risks on an ongoing basis. These protocolsare based upon current medical and scientific knowledge of PML andinformation gained from the safety evaluation of natalizumab-treatedpatients.

This information provides a setting wherein appropriate patients receivenatalizumab. Accordingly, the invention provides that patients andphysicians receive significant information regarding the risksassociated with natalizumab so that informed benefit-risk decisions canbe made regarding initiation of natalizumab treatment.

The invention also provides that the prescription for natalizumab servesas an enrollment form for physicians and for patients that collectsinformation regarding risk factors for PML, and requires anacknowledgement by physicians and patients that they understand therisks associated with natalizumab treatment.

Infusion sites undergo a mandatory authorization process that must becompleted prior to shipment of natalizumab to that site. A controlled,centralized, distribution system ships natalizumab only to authorizedinfusion sites, allowing for directed delivery of informational toolsand timely receipt of new safety information. The shipping destinationand the number of all vials are tracked through the distribution system.Through the controlled distribution system, all physicians and patientswho use natalizumab at initiation of treatment PML are enrolled in asurveillance program that continues informing about and assessing therisk of PML. For example, large registry studies continually assess thesafety of natalizumab in the commercial setting.

The surveillance program monitors patients receiving natalizumabtreatment by routinely assessing them for PML, using the opportunityafforded through the periodic interactions between the heath careproviders and patients at the time of infusion. In an embodiment, theseperiodic interactions occur approximately once a month. Patients withpossible PML are thus rapidly identified, so that natalizumab can beimmediately discontinued and the proper assessments completed. Thisinformation, surveillance, and monitoring program provides timelyinformation regarding safety issues related to natalizumab.

Additional objects and advantages of the invention will be set forth inpart in the description which follows, and in part will be obvious fromthe description, or may be learned by practice of the invention. Theobjects and advantages of the invention will be realized and attained bymeans of the elements and combinations particularly pointed out in theappended claims. Moreover, advantages described in the body of thespecification, if not included in the claims, are not per se limitationsto the claimed invention.

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are not restrictive of the invention, as claimed. Moreover, it mustbe understood that the invention is not limited to the particularembodiments described, as such may, of course, vary. Further, theterminology used to describe particular embodiments is not intended tobe limiting, since the scope of the present invention will be limitedonly by its claims. The claims do not encompass embodiments in thepublic domain.

With respect to ranges of values, the invention encompasses eachintervening value between the upper and lower limits of the range to atleast a tenth of the lower limit's unit, unless the context clearlyindicates otherwise. Further, the invention encompasses any other statedintervening values. Moreover, the invention also encompasses rangesexcluding either or both of the upper and lower limits of the range,unless specifically excluded from the stated range.

Unless defined otherwise, the meanings of all technical and scientificterms used herein are those commonly understood by one of ordinary skillin the art to which this invention belongs. One of ordinary skill in theart will also appreciate that any methods and materials similar orequivalent to those described herein can also be used to practice ortest the invention. The specification is most thoroughly understood inlight of the references cited herein.

It must be noted that, as used herein and in the appended claims, thesingular forms “a,” “or,” and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “asubject polypeptide” includes a plurality of such polypeptides andreference to “the agent” includes reference to one or more agents andequivalents thereof known to those skilled in the art, and so forth.

Further, all numbers expressing quantities of ingredients, reactionconditions, % purity, polypeptide and polynucleotide lengths, and soforth, used in the specification and claims, are modified by the term“about,” unless otherwise indicated. Accordingly, the numericalparameters set forth in the specification and claims are approximationsthat may vary depending upon the desired properties of the presentinvention. At the very least, and not as an attempt to limit theapplication of the doctrine of equivalents to the scope of the claims,each numerical parameter should at least be construed in light of thenumber of reported significant digits, applying ordinary roundingtechniques. Nonetheless, the numerical values set forth in the specificexamples are reported as precisely as possible. Any numerical value,however, inherently contains certain errors from the standard deviationof its experimental measurement.

EXAMPLES

The examples, which are intended to be purely exemplary of the inventionand should therefore not be considered to limit the invention in anyway, also describe and detail aspects and embodiments of the inventiondiscussed above. The examples are not intended to represent that theexperiments below are all or the only experiments performed. Effortshave been made to ensure accuracy with respect to numbers used (forexample, amounts, temperature, etc.) but some experimental errors anddeviations should be accounted for. Unless indicated otherwise, partsare parts by weight, molecular weight is weight average molecularweight, temperature is in degrees Centigrade, and pressure is at or nearatmospheric.

Example 1: Efficacy of Natalizumab

The efficacy of natalizumab over a two year period has been demonstratedin two Phase 3 trials (Polman et al., N. Engl. J. Med. in press (2006);Rudick et al. N. Engl. J. Med. in press (2006)). In one study,natalizumab was given as monotherapy to treatment-naïve MS patients andits efficacy was compared to placebo. In the other study, natalizumabwas given to patients who were experiencing relapses despite concurrentAVONEX® therapy and its efficacy was compared to that of AVONEX(interferon β-1a) plus placebo. Data through two years have confirmedthe benefit that led to accelerated approval at one year. These datashow that natalizumab is highly efficacious in delaying the time toonset of sustained progression of disability, in reducing annualizedrelapse rate, in attenuating MRI lesions, and in improving the qualityof life of patients compared both to placebo and the active AVONEX®control group.

Both Phase 3 studies had similar designs. In the monotherapy study, 942untreated relapsing remitting MS patients were randomized to receivenatalizumab or placebo for 120 weeks (30 infusions) using a 2:1allocation. In the add-on study, 1,171 patients who had been receivingweekly intramuscular injections of 30 μg AVONEX®, but who had relapseddespite this treatment, were randomized using a 1:1 allocation to addnatalizumab or placebo to their regimen, also for 120 weeks.

Efficacy parameters included EDSS scores, MS relapses, brain MRI scans,MSFC scores, visual function tests, and quality of life. EDSS and MSFCwere measured every 12 weeks, brain MRI scans and quality of lifequestionnaires at baseline and every year, and MS relapses on an ongoingbasis.

Treatment with natalizumab as monotherapy in treatment-naïve patientshad profound effects on the time to onset of sustained progression indisability and on annualized relapse rate, the two primary endpoints, asshown in Table 2. These significant effects were confirmed versusAVONEX® alone.

TABLE 2 Efficacy of Natalizumab in Phase 3 Studies Add-on therapyMonotherapy AVONEX + 300 mg AVONEX + 300 mg Placebo natalizumab placebonatalizumab Number of patients 315 627 582 589 Percentage of 29% 17% 29%23% patients with sustained progression of disability Hazard ratio (95%0.58 (0.43, 0.77) 0.76 (0.61, 0.96) confidence interval) Risk reduction42% 24% p-value p < 0.001 p = 0.024 Annualized 0.733 0.235 0.749 0.336relapse rate Relative reduction 68% 55% p-value p < 0.001 p < 0.001

The patient population in the two Phase 3 studies were relapsing MSpatients according to the criteria of the International Panel on theDiagnosis of Multiple Sclerosis (McDonald et al., Ann. Neurol.50:121-127 (2001)). It encompassed a broad range of ages and diseaseseverity, and represented the current relapsing MS population withactive disease, consistent with the approved indication. Patients withprimary- or secondary-progressive MS were excluded.

The patient populations targeted for the two studies differed. Patientsin the monotherapy study were essentially naïve to treatment with animmunomodulatory drug for MS. Specifically, patients may not have hadtreatment with any immunomodulator (β-interferon or glatiramer acetate)for a period longer than six months and not within six months of thebeginning of the study. The result was a young, mostly female, MSpopulation with a moderate degree of baseline disease activity (typicalof the general MS population), very few of whom had tried anotherimmunomodulator prior to study entry.

Patients in the add-on therapy study were required to have receivedAVONEX® for the previous year and to have had a relapse during that timewhile on AVONEX® treatment. This resulted in a population somewhat olderthan that in the monotherapy study, with a longer disease duration.However, patients in the add-on therapy study had a similar degree ofdisease activity as those in the monotherapy study, despite AVONEX®treatment.

Example 2: Caregiver and Patient Information

Prior to starting natalizumab treatment, the physician will provide thepatient with the Patient Information Leaflet, will ask the patient toread it, and will discuss the information with the patient. The PatientInformation Leaflet is intended to provide information to patients withMS on the risks of natalizumab treatment, including the risk of PML. Inaddition, the leaflet instructs patients to promptly report anycontinuously worsening neurological symptoms to their physician, therebyreinforcing the importance of early detection of PML. The PatientInformation Leaflet will be widely disseminated. In addition todistribution to prescribers and infusion centers, the leaflet will beavailable on the internet and distributed to patient groups such as theNational Multiple Sclerosis Society (NMSS).

Once the decision to use natalizumab is made, the physician and patientwill complete the enrollment form. The enrollment form includes anatalizumab prescription and a Patient-Physician Acknowledgement. Thephysician and patient will sign the Patient-Physician Acknowledgment todocument that they discussed and understood natalizumab benefits andrisks, including the risk of PML, and that the physician is prescribingnatalizumab for the treatment of relapsing MS.

By signing the Patient-Physician Acknowledgement, the physician alsoacknowledges that he or she has read the full prescribing informationfor natalizumab, is aware that natalizumab is associated with anincreased risk of PML, which causes death or disability, has discussedthe risks and benefits of natalizumab with his or her patient, and isprescribing natalizumab for the treatment of relapsing MS. The physicianalso acknowledges that the patient is not immunocompromised, and hasinstructed the patient to promptly report to his or her physician anycontinuously worsening symptoms that persist over several days.

By signing the Patient-Physician Acknowledgement, the patientacknowledges that he or she has read the Patient Information Leaflet, isaware that natalizumab is associated with an increased risk of PML,which causes death and disability, has discussed the risks and benefitsof natalizumab with his or her physician, and understands that it isimportant to promptly report to his or her physician any continuouslyworsening symptoms lasting over several days. The patient and physicianinformation are entered into a central database, thus initiatingenrollment into the natalizumab risk management program.

Each enrolled patient is assigned a case manager who can answerquestions about natalizumab, provide insurance coverage research, andmatch the patient to an appropriate infusion center. These services willbe provided again upon natalizumab re-introduction and are anotherreason for patients and physicians to use the enrollment form. Inaddition, informational materials for natalizumab will inform physiciansof the need to use the enrollment form for all natalizumab-treatedpatients and Biogen Idec and Elan sales representatives will be trainedto reinforce the importance of using the form with all neurologists.Finally, neurologists and MS patients have provided feedback on thenatalizumab risk management program and strongly support the use of theenrollment form. With the re-introduction of natalizumab, proceduresdescribed herein will be monitored.

The invention claimed is:
 1. A method of using natalizumab to treat apatient with an inflammatory or autoimmune disease, the methodcomprising: (a) testing the patient for the presence of anti-JC virus(JCV) antibodies by a method consisting of determining a presence orabsence of anti-JCV antibodies in serum or plasma of a blood sample of apatient; (b) identifying the patient as having serum or plasma that isnegative for anti-JCV antibodies; and (c) initiating natalizumabtreatment of the patient having serum or plasma that is negative foranti-JCV antibodies, wherein the testing of (a) improves the safety ofthe natalizumab treatment.
 2. The method of claim 1, further comprising:(d) monitoring the patient for indicators of progressive multifocalleukoencephalopathy (PML) after initiating natalizumab treatment of thepatient, wherein the testing of (a) and monitoring of (d) improve thesafety of the natalizumab treatment.
 3. The method of claim 2, furthercomprising discontinuing the administration of natalizumab in thepresence of the indicators of PML.
 4. The method of claim 2, wherein theindicators of PML comprise new or worsening neurological symptoms. 5.The method of claim 4, wherein the neurological symptoms comprise one ormore of central blindness, mental confusion, personality change, anddyskinesia.
 6. The method of claim 2, wherein the monitoring the patientfor indicators of PML after initiating natalizumab treatment of thepatient comprises detecting the presence of JCV in the patient'scerebrospinal fluid.
 7. The method of claim 2, wherein the monitoringthe patient for indicators of PML after initiating natalizumab treatmentof the patient comprises serially removing samples of the patient'sblood, measuring the amount of IgG antibodies to JCV in the samples, andcomparing the amount of the antibodies in the samples.
 8. The method ofclaim 7, wherein the monitoring the patient for indicators of PMLfurther comprises: (i) detecting seroconversion or an increasing titerof JCV by the comparing the amount of the antibodies in the samples;(ii) removing a sample of the patient's cerebrospinal fluid afterdetecting the seroconversion or increasing titer of JCV; and (iii)testing the cerebrospinal fluid for the presence of JCV.
 9. The methodof claim 2, wherein the indicators of PML comprise new or worseningradiological symptoms.
 10. The method of claim 9, wherein the radiologicsymptoms comprise lesions detected by a Gd-enhanced magnetic resonanceimaging scan.
 11. The method of claim 1, wherein the inflammatory orautoimmune disease is multiple sclerosis.
 12. The method of claim 11,wherein the multiple sclerosis is selected from relapsing remitting,secondary progressive, primary progressive, and chronic progressivemultiple sclerosis.
 13. The method of claim 12, wherein the multiplesclerosis (MS) is relapsing remitting MS.
 14. The method of claim 12,wherein the multiple sclerosis (MS) is secondary progressive MS.
 15. Themethod of claim 12, wherein the multiple sclerosis (MS) is primaryprogressive MS.
 16. The method of claim 12, wherein the multiplesclerosis is chronic progressive multiple sclerosis.
 17. The method ofclaim 1, wherein the disease is inflammatory bowel disease.
 18. Themethod of claim 17, wherein the inflammatory bowel disease is Crohn'sdisease.
 19. The method of claim 1, wherein the disease is rheumatoidarthritis.